Please login to the form below

Not currently logged in
Email:
Password:

Orbactiv

This page shows the latest Orbactiv news and features for those working in and with pharma, biotech and healthcare.

Actavis gets FDA nod for new antibiotic

Actavis gets FDA nod for new antibiotic

dalbavancin) and The Medicine Company's Orbactiv (oritavancin).

Latest news

  • Antibiotics among 7 new drugs backed by EMA Antibiotics among 7 new drugs backed by EMA

    Antibiotics among 7 new drugs backed by EMA. The Medicines Company’ s Orbactiv and Cubist’ s Sivextro set for European approval. ... Orbactiv and Sivextro are already recommended by the US FDA to treat these forms of infections.

  • FDA backs Cubist's antibiotic Zerbaxa FDA backs Cubist's antibiotic Zerbaxa

    In addition to Sivextro, the agency also gave a green light this year to Durata Therapeutics' Dalvance (dalbavancin) - recently acquired by Actavis - and The Medicines Company's Orbactiv (oritavancin).

  • Actavis buys infectious disease specialist Durata Actavis buys infectious disease specialist Durata

    Cubicin (daptomycin) and Sivextro (tidezolid) and The Medicine Company's Orbactiv (oritavancin) in the ABSSSI category.

  • FDA approves antibacterial skin drug Orbactiv FDA approves antibacterial skin drug Orbactiv

    FDA approves antibacterial skin drug Orbactiv. US regulator authorises Medicines Company's treatment for ABSSSI. ... The Food and Drug Administration has approved antibacterial drug Orbactiv (oritavancin) to treat adults with acute bacterial skin and

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Grace Communications

Grace Communications is a creative agency specialising in healthcare communication and understanding people's personality types....

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics